<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37029">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02624479</url>
  </required_header>
  <id_info>
    <org_study_id>009_15</org_study_id>
    <nct_id>NCT02624479</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study to Investigate the Bioavailability and Tolerability of 3 Oral Formulations of Sodium Thiosulfate</brief_title>
  <acronym>TSTS</acronym>
  <official_title>Phase I Pharmacokinetic Pilot Study to Investigate the Bioavailability and Tolerability of Three Different Oral Formulations of Sodium Thiosulfate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic treatment and prophylaxis of vessel and soft tissue calcification as well as of
      renal calculi could be a future indication for sodium thiosulfate (STS). Using an oral
      formulation might increase the compliance and treatment success compared to parenteral
      administration.

      Three gastro-resistant formulations of STS for oral administration were developed with
      different release characteristics: fast-release, medium-release and slow-release tablets.
      Aim of the enteric coating was to increase the oral bioavailability of STS. The
      bioavailability and tolerability of these formulations for oral administration in healthy
      volunteers will be compared in this clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2016</start_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative bioavailability of STS after oral administration based on urinary excretion of TS and sulfate</measure>
    <time_frame>7 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>7 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TS excretion in urine</measure>
    <time_frame>48 hours</time_frame>
    <description>amount excreted within 48h and fraction (amount/dose) of administered thiosulfate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TS excretion in urine: amount</measure>
    <time_frame>48 hours</time_frame>
    <description>amount excreted within 48h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TS excretion in urine: fraction of administered TS</measure>
    <time_frame>48 hours</time_frame>
    <description>excreted / administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sulfate excretion in urine: amount</measure>
    <time_frame>48 hours</time_frame>
    <description>amount excreted within 48h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sulfate excretion in urine: fraction of administered TS</measure>
    <time_frame>48 hours</time_frame>
    <description>excreted / administered</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Fast first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium thiosulfate fast release formulation first, followed by medium and slow</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium thiosulfate medium release formulation first, followed by slow and fast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Slow first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sodium thiosulfate slow release formulation first, followed by fast and medium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium thiosulfate</intervention_name>
    <description>oral administration of thiosulfate</description>
    <arm_group_label>Fast first</arm_group_label>
    <arm_group_label>Medium first</arm_group_label>
    <arm_group_label>Slow first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female healthy subjects â‰¥ 18 years

          -  Negative pregnancy test in female subjects of childbearing age

          -  Able to understand character and individual consequences of the clinical trial and to
             provide written informed consent to participate in the study

        Exclusion Criteria:

          -  Pregnant or lactating subjects.

          -  Renal impairment (creatinine clearance &lt;60ml/min)

          -  Concomitant medication

          -  Gastrointestinal diseases

          -  History of alcohol abuse, illicit drug use, significant mental illness, physical
             dependance to opioid, other drug abuse or addiction (last 12 months)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominik Uehlinger, Prof Dr.med.</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Pasch, Dr. med.</last_name>
    <email>andreas.pasch@insel.ch</email>
  </overall_contact>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 10, 2016</lastchanged_date>
  <firstreceived_date>November 26, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sodium thiosulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
